What's new? Log in Free sign up

Filing search / Kineta, Inc. / "Responsibility"

Search information

Kineta, Inc.

Companies

"Responsibility"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

117 results

Newest first Best match first

KANT Kineta, Inc.

Quarterly report

in development milestones, sales milestones and royalties on net sales. Following this milestone, Merck will assume sole responsibility for all future … responsibility for all future development and commercialization for the ALS program. The Company recognized licensing revenues of zero for the three

8 Aug 24

4:00pm

KANT Kineta, Inc.

Quarterly report

. Following this milestone, Merck will assume sole responsibility for all future development and commercialization for the ALS program. The Company

15 May 24

4:05pm

KANT Kineta, Inc.

Definitive proxy

biotechnology companies. Previously, she was the CFO at EPIX Pharmaceuticals, Inc. and also spent ten years in roles of increasing responsibility … . Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller

26 Apr 24

4:00pm

KANT Kineta, Inc.

or responsibility related to the Restatement. Notwithstanding the foregoing, if the Company is required to undertake a Restatement, the Company will not be required

21 Mar 24

4:06pm

KANT Kineta, Inc.

sole responsibility for all future development and commercialization for the ALS program. Genentech, Inc. In connection with the Merger, Kineta became … Therapeutics assumed sole responsibility for all future development and commercialization of the licensed products. These license agreements offer

21 Mar 24

4:06pm

s2lc f91xdsaovl2q

Prospectus supplement

Shelf registration

3 Nov 23

4:25pm

Quarterly report

3 Nov 23

4:04pm

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

fgtbdo69vvnb4ek

Prospectus supplement for primary offering

vblw22tx7tq drqpft

Quarterly report

11 Aug 23

4:07pm

t4jbhjvni3ghua chw

Kineta to Receive $5 Million Milestone Payment from Merck

txu x98hx47pinpj

Kineta to Receive $5 Million Milestone Payment from Merck

Departure of Directors or Certain Officers

Prospectus supplement

Shelf registration

1 Jun 23

4:01pm

z62a1am2clut uvih0c

Definitive proxy

28 Apr 23

5:09pm

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Prospectus supplement for primary offering

31 Mar 23

4:05pm

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.